Table V.
Relationship between serum CT and CEA levels and different clinicopathological features of the patients with MTC.
| Groups | N | CT (pg/ml) | U | P-value | CEA (ng/ml) | U | P-value |
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Male | 21 | 362.19 (58.86, 1210.45) | 425.300 | >0.05 | 46.67 (8.12, 114.61) | 466.900 | >0.05 |
| Female | 28 | 329.24 (75.67, 1015.36) | 39.82 (11.23, 98.67) | ||||
| Age (years) | |||||||
| ≤50 | 23 | 327.16 (81.43, 986.75) | 619.200 | >0.05 | 37.54 (12.36, 96.34) | 568.300 | >0.05 |
| >50 | 16 | 359.78 (61.43, 1225.34) | 47.61 (9.13, 116.78) | ||||
| Tumor diameter (cm) | |||||||
| ≤1 | 12 | 102.33 (31.42, 186.31) | 89.000 | <0.01 | 26.54 (6.79, 35.27) | 93.000 | <0.01 |
| >1 | 27 | 489.43 (125.42, 1361.27) | 68.79 (37.68, 120.67) | ||||
| Lymph node metastasis | |||||||
| Yes | 18 | 782.34 (213.56, 1364.21) | 102.000 | <0.01 | 86.79 (43.22, 33.24) | 113.000 | <0.01 |
| No | 21 | 95.13 (21.56, 159.45) | 18.67 (7.64, 32.77) | ||||
| Before and after treatment | |||||||
| Before treatment | 39 | 345.35 (69.34, 1123.44) | 236.000 | <0.01 | 42.75 (10.67, 102.45) | 201.000 | <0.01 |
| After treatment | 39 | 5.26 (2.63, 7.34) | 4.32 (2.17, 5.25) | ||||
CT, calcitonin; CEA, carcinoembryonic antigen; MTC, medullary thyroid carcinoma. Data are expresses as [mean (25–75%)].